Physician profile
Gary E Kay
NPI 1205897923
$314,085.16
in general payments reported to CMS, 2019-2025
73 companies · $2,040 in 2025
The $2,040 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129K · 2020: $41K · 2021: $52K · 2022: $32K · 2023: $43K · 2024: $15K · 2025: $2,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Consulting Fee: $9,518 · Food and Beverage: $6,028 · Travel and Lodging: $4,218 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,971.00 |
| Consulting Fee | $9,517.50 |
| Food and Beverage | $6,028.49 |
| Travel and Lodging | $4,217.68 |
| Education | $120.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $134,783.24 | 2019-2024 | Verzenio, Jaypirca |
| Seagen INC. | $38,086.00 | 2019-2023 | Adcetris, Padcev |
| Amgen INC. | $24,239.40 | 2019-2023 | Kyprolis |
| Kite Pharma, INC. | $18,495.25 | 2020-2023 | Yescarta |
| Coherus Oncology, INC. | $15,238.40 | 2021-2023 | |
| Gilead Sciences, INC. | $14,637.08 | 2019-2024 | |
| Heron Therapeutics, INC. | $14,504.52 | 2019-2025 | Cinvanti |
| Pfizer INC. | $9,963.46 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $9,657.44 | 2019-2025 | |
| Dova Pharmaceuticals | $8,493.43 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $2,102.89 | 2019-2024 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $1,986.60 | 2019-2024 | Carvykti, Erleada, Tecvayli |
| Glaxosmithkline, LLC. | $1,899.74 | 2020-2024 | Zejula, Jemperli |
| Astrazeneca Pharmaceuticals Lp | $1,876.72 | 2019-2025 | Imfinzi, Enhertu, Wainua |
| Asd Specialty Healthcare, LLC | $1,691.44 | 2019-2025 |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.